These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PHOTON-2: hope for patients with HIV and HCV co-infection? Naggie S; Kim AY Lancet; 2015 Mar; 385(9973):1052-4. PubMed ID: 25659286 [No Abstract] [Full Text] [Related]
3. Shorter treatments for hepatitis C: another step forward? Foster GR Lancet; 2015 Mar; 385(9973):1054-5. PubMed ID: 25591504 [No Abstract] [Full Text] [Related]
4. Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3. Bari K; Sharma P Gastroenterology; 2014 Aug; 147(2):534-6. PubMed ID: 24953626 [No Abstract] [Full Text] [Related]
6. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Yoshida EM; Sulkowski MS; Gane EJ; Herring RW; Ratziu V; Ding X; Wang J; Chuang SM; Ma J; McNally J; Stamm LM; Brainard DM; Symonds WT; McHutchison JG; Beavers KL; Jacobson IM; Reddy KR; Lawitz E Hepatology; 2015 Jan; 61(1):41-5. PubMed ID: 25314116 [TBL] [Abstract][Full Text] [Related]
7. Daclatasvir plus sofosbuvir for HCV infection. Sulkowski MS; Jacobson IM; Nelson DR N Engl J Med; 2014 Apr; 370(16):1560-1. PubMed ID: 24738674 [No Abstract] [Full Text] [Related]
8. Daclatasvir plus sofosbuvir for HCV infection. Dhaliwal HS; Nampoothiri RV N Engl J Med; 2014 Apr; 370(16):1560. PubMed ID: 24738675 [No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of new drugs for chronic hepatitis C: the importance of updating utility values. Cortesi PA; Scalone L; Mantovani LG Hepatology; 2015 Mar; 61(3):1096-7. PubMed ID: 25043465 [No Abstract] [Full Text] [Related]
10. Hepatitis C genotype 3: a tough match for interferon-free regimens. Aghemo A; Colombo M Gastroenterology; 2014 Apr; 146(4):1125-7. PubMed ID: 24566101 [No Abstract] [Full Text] [Related]
11. [Begin of a new era in treating hepatitis C in Patients on the waiting list and after liver transplantation]. Beckebaum SK; Schmidt HH Z Gastroenterol; 2014 Jul; 52(7):746-8. PubMed ID: 25026012 [No Abstract] [Full Text] [Related]
12. Therapy for hepatitis C--the costs of success. Hoofnagle JH; Sherker AH N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236 [No Abstract] [Full Text] [Related]
13. Sovaldi ushers in wave of costly hepatitis C drugs. Manag Care; 2014 Jan; 23(1):51. PubMed ID: 24765752 [No Abstract] [Full Text] [Related]
14. [Sofosbuvir: alternative in hepatitis C infection?]. Blum HE Dtsch Med Wochenschr; 2013 Aug; 138(33):1646-7. PubMed ID: 23913349 [No Abstract] [Full Text] [Related]
15. Therapy: Retreatment of HCV infection in DAA nonresponders. Ray K Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):252. PubMed ID: 25895827 [No Abstract] [Full Text] [Related]
16. Are we hopefully very close to the end of HCV? Tahan V Turk J Gastroenterol; 2014 Apr; 25(2):230-1. PubMed ID: 25003693 [No Abstract] [Full Text] [Related]
17. Sofosbuvir for previously untreated chronic hepatitis C infection. Lawitz E; Gane EJ N Engl J Med; 2013 Aug; 369(7):678-9. PubMed ID: 23944316 [No Abstract] [Full Text] [Related]
18. Sofosbuvir for previously untreated chronic hepatitis C infection. Hsu CS N Engl J Med; 2013 Aug; 369(7):678. PubMed ID: 23944317 [No Abstract] [Full Text] [Related]
19. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. Ollendorf DA; Tice JA; Pearson SD JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321 [No Abstract] [Full Text] [Related]
20. A cure for the high cost of hepatitis C virus treatment. Etzion O; Ghany MG Ann Intern Med; 2015 May; 162(9):660-1. PubMed ID: 25820765 [No Abstract] [Full Text] [Related] [Next] [New Search]